In another study, considering that subunit vaccines have been studied in several cancer immunotherapy clinical trials with limited efficacy and that nanovaccines can improve efficacy but are rarely translated clinically, Zhu et al. combined Evans blue (EB) derivative (MEB) with molecular vaccines to form the nanovaccine AlbiVax, which could bind to albumin molecules to form albumin/AlbiVax in vivo for efficiently co-delivering adjuvant and peptide Ag into LNs [143]. Here, ALB is linked to cancer.